NASDAQ:BVXV

BiondVax Pharmaceuticals - BVXV Stock Forecast, Price & News

$1.21

-0.03 (-2.42%)

(As of 08/17/2022 05:17 PM ET)

Add

Compare

Today's Range: $1.19
▼
$1.23
50-Day Range: $1.16
▼
$1.34
52-Week Range: $1.00
▼
$3.49

Volume: 17,747 shs
Average Volume: 583,691 shs
Market Capitalization: $13.74 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

BiondVax Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 478.5% Upside
$7.00 Price Target
Short Interest: Healthy
0.28% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.48
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

643rd out of 1,122 stocks

Biological Products, Except Diagnostic Industry

98th out of 178 stocks

3.5

Analyst's Opinion

Consensus Rating
BiondVax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, BiondVax Pharmaceuticals has a forecasted upside of 478.5% from its current price of $1.21.
Amount of Analyst Coverage
BiondVax Pharmaceuticals has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.28% of the outstanding shares of BiondVax Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
BiondVax Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BiondVax Pharmaceuticals has recently decreased by 18.21%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
BiondVax Pharmaceuticals does not currently pay a dividend.
Dividend Growth
BiondVax Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BVXV.

3.6

News and Social Media Coverage

News Sentiment
BiondVax Pharmaceuticals has a news sentiment score of 1.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for BiondVax Pharmaceuticals this week, compared to 0 articles on an average week.
MarketBeat Follows
2 people have added BiondVax Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BiondVax Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.03% of the stock of BiondVax Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 2.96% of the stock of BiondVax Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for BiondVax Pharmaceuticals are expected to remain at ($0.02) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of BiondVax Pharmaceuticals is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BiondVax Pharmaceuticals is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BiondVax Pharmaceuticals has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BiondVax Pharmaceuticals (NASDAQ:BVXV) Stock

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

BiondVax Pharmaceuticals Stock Performance

Shares of NASDAQ:BVXV traded down $0.03 during midday trading on Wednesday, hitting $1.21. The stock had a trading volume of 7 shares, compared to its average volume of 30,346. The company's 50-day moving average price is $1.21 and its 200-day moving average price is $1.32. BiondVax Pharmaceuticals has a fifty-two week low of $1.00 and a fifty-two week high of $3.49. The company has a debt-to-equity ratio of 4.03, a current ratio of 5.82 and a quick ratio of 5.82.

BiondVax Pharmaceuticals (NASDAQ:BVXV - Get Rating) last released its quarterly earnings data on Wednesday, June 1st. The company reported ($0.20) earnings per share (EPS) for the quarter. Research analysts predict that BiondVax Pharmaceuticals will post -0.02 EPS for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of BiondVax Pharmaceuticals in a research report on Wednesday. They issued a "sell" rating for the company.

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Stock News Headlines

August 10, 2022 | finance.yahoo.com

BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy

August 10, 2022 | americanbankingnews.com

BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by Analysts at StockNews.com

August 2, 2022 | investing.com

BVXV_t5 Historical Data

August 2, 2022 | americanbankingnews.com

BiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated by Analysts at StockNews.com

July 26, 2022 | americanbankingnews.com

StockNews.com Initiates Coverage on BiondVax Pharmaceuticals (NASDAQ:BVXV)

June 27, 2022 | finance.yahoo.com

BVXV: Significant Progress Made in NanoAb Program…

June 7, 2022 | finance.yahoo.com

BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trial

June 3, 2022 | seekingalpha.com

Biondvax Pharmaceuticals reports Q1 results

June 1, 2022 | investing.com

BiondVax Pharma Reports Q1 Results

June 1, 2022 | finance.yahoo.com

BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update

May 19, 2022 | finance.yahoo.com

BiondVax to Present at H.C. Wainwright Global Investment Conference

May 9, 2022 | finance.yahoo.com

BiondVax to Present at this week's Biomed Israel Conference

May 2, 2022 | finance.yahoo.com

BVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies…

April 5, 2022 | finance.yahoo.com

BiondVax to host a Hebrew-language analyst and investor webinar on April 6th

March 31, 2022 | finance.yahoo.com

BiondVax to host analyst and investor webinar on April 4th

March 29, 2022 | seekingalpha.com

Biondvax Pharmaceuticals GAAP EPS of -NIS0.07

March 28, 2022 | finance.yahoo.com

BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

March 24, 2022 | benzinga.com

Here's Why Biondvax Pharmaceuticals Shares Are Rising

March 24, 2022 | finance.yahoo.com

Why Are BiondVax Pharma Shares Gaining Today?

March 24, 2022 | msn.com

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

March 24, 2022 | seekingalpha.com

BiondVax stock soars 15% on research pact to develop nanosized antibody therapies

March 24, 2022 | finance.yahoo.com

BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies

March 14, 2022 | finance.yahoo.com

European Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for BiondVax's New Strategy

February 22, 2022 | finance.yahoo.com

BiondVax to Present at Aegis Virtual Conference

February 15, 2022 | finance.yahoo.com

BiondVax to Present at BIO CEO & Investor Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Company Calendar

Last Earnings: 6/01/2022
Today: 8/17/2022
Next Earnings (Estimated): 8/25/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BVXV
CUSIP: N/A
CIK: 1611747
Web: www.biondvax.com
Phone: 9723029302529
Fax: 972-8930-2531
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +478.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,850,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -304.68%
Return on Assets: -46.37%

Debt

Debt-to-Equity Ratio: 4.03
Current Ratio: 5.82
Quick Ratio: 5.82

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.66 per share
Price / Book: 1.83

Miscellaneous

Outstanding Shares: 11,354,000
Free Float: 10,669,000
Market Cap: $13.74 million
Optionable: Not Optionable
Beta: 2.35

Key Executives

Mr. Amir Reichman M.B.A. (Age 46)
M.Sc., CEO & Director
Mr. Uri Ben-Or CPA (Age 52)
CPA, M.B.A., MBA, Chief Financial Officer
Mr. Elad Mark B.Sc. (Age 40)
Eng., M.B.A., Chief Operating Officer
Dr. Tamar Ben-Yedidia Ph.D. (Age 58)
Chief Scientist
Mr. Joshua E. Phillipson B.Sc.
M.B.A., Director of Bus. Devel. & Investor Relations
Ms. Moran Ahdout Fruchter L.L.B.
Chief of Staff
Ms. Dalit Weinstein Fischer
Head of Technical R&D

Key Competitors

View All Competitors

Insiders & Institutions

Envestnet Asset Management Inc.
Bought 113,418 shares on 8/3/2022
Ownership: 1.439%

View All Insider Transactions
View All Institutional Transactions

BVXV Stock - Frequently Asked Questions

Should I buy or sell BiondVax Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BiondVax Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BVXV shares.
View BVXV analyst ratings or view top-rated stocks.
What is BiondVax Pharmaceuticals' stock price forecast for 2022?: 1 Wall Street analysts have issued twelve-month price objectives for BiondVax Pharmaceuticals' shares. Their BVXV share price forecasts range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 478.5% from the stock's current price.
View analysts price targets for BVXV or view top-rated stocks among Wall Street analysts.
How have BVXV shares performed in 2022?: BiondVax Pharmaceuticals' stock was trading at $2.35 at the beginning of 2022. Since then, BVXV stock has decreased by 48.5% and is now trading at $1.21.
View the best growth stocks for 2022 here.
When is BiondVax Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 25th 2022.
View our BVXV earnings forecast.
How were BiondVax Pharmaceuticals' earnings last quarter?: BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) issued its earnings results on Wednesday, June, 1st. The company reported ($0.20) earnings per share (EPS) for the quarter.
What other stocks do shareholders of BiondVax Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?: (BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.
What is BiondVax Pharmaceuticals' stock symbol?: BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."
Who are BiondVax Pharmaceuticals' major shareholders?: BiondVax Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (1.44%).
How do I buy shares of BiondVax Pharmaceuticals?: Shares of BVXV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BiondVax Pharmaceuticals' stock price today?: One share of BVXV stock can currently be purchased for approximately $1.21.
How much money does BiondVax Pharmaceuticals make?: BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $13.73 million. The company earns $-12,850,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.
How can I contact BiondVax Pharmaceuticals?: BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for the company is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at j.phillipson@biondvax.com, or via fax at 972-8930-2531.

This page (NASDAQ:BVXV) was last updated on 8/17/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

BiondVax Pharmaceuticals - BVXV Stock Forecast, Price & News

BiondVax Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month